VistaGen Therapeutics, Inc.
VTGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | -0.16 | 0.32 | -0.17 |
| FCF Yield | -10.89% | -29.51% | -13.22% | -11.35% |
| EV / EBITDA | -3.43 | -1.15 | -0.78 | -1.18 |
| Quality | ||||
| ROIC | -29.26% | -26.63% | -20.05% | -18.15% |
| Gross Margin | 100.00% | 30.74% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.71 | 1.25 | 0.74 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.81% | – | – | – |
| Free Cash Flow Growth | 26.67% | -85.67% | 1.26% | 5.20% |
| Safety | ||||
| Net Debt / EBITDA | 3.17 | 3.12 | 4.58 | 4.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -258.82 | 0.00 | 0.00 |